Wegovy And Zepbound Doses Available Again After Months Of Shortages, FDA Says—But Supplies Are Still Limited

Forbes Business Breaking Wegovy And Zepbound Doses Available Again After Months Of Shortages, FDA Says—But Supplies Are Still Limited Robert Hart Forbes Staff Robert Hart is a London-based Forbes senior reporter. Following Aug 7, 2024, 07:28am EDT Share to Facebook Share to Twitter Share to Linkedin Topline More doses of Novo Nordisk’s popular weight loss
Wegovy And Zepbound Doses Available Again After Months Of Shortages, FDA Says—But Supplies Are Still Limited

Wegovy And Zepbound Doses Available Again After Months Of Shortages, FDA Says—But Supplies Are Still Limited

Following

Topline

More doses of Novo Nordisk’s popular weight loss drug Wegovy are back in stock in the U.S. after years of shortages and just days after all doses of Eli Lilly’s rival injection Zepbound became available, according to an update on the Food and Drug Administration’s website, though shortages are set to continue as pharma struggles to ramp up production..

Key Facts

The 0.5 milligram (mg) and 1 milligram doses of Wegovy injections are listed as available on the FDA’s drug shortage database following an update on Tuesday.

The drug, known generically as semaglutide and sold as Ozempic to treat diabetes, has featured on the regulator’s shortages list for more than two years due to high demand and Novo Nordisk said it restricted access to lower doses used to start treatment to ensure people already using the injections can continue to access the medicine.

Only the smallest Wegovy dose, a 0.25 milligram injector, remains listed as “limited availability” on the FDA database after an update in late April listed the second-highest dose—a 1.7 milligram injection—become the second listed as available following the largest 2.4 milligram dose, a 2.4 milligram injector pen.

The agency said it is not clear how long the shortage for the smaller dose will last and Novo Nordisk has not indicated when the shortages may end, though it is working to ramp up production.

Last week, an update to the FDA database listed Eli Lilly’s tirzepatide, the generic drug inside the company’s branded weight loss and diabetes therapies Zepbound and Mounjaro, as “available” in all doses after being added to the shortages list in April.

Despite the update, the FDA has not removed tirzepatide or semaglutide injectors from its shortages list and it’s unclear when, or if, and under what conditions it would do so.


What’s Driving The Shortage Of Glp-1 Weight Loss And Diabetes Drugs Like Ozempic?

Novo’s semaglutide and Lilly’s tirzepatide are at the forefront of a promising and growing class of drugs called GLP-1 agonists, which can help control hunger and blood sugar by mimicking the action of gut hormones. While GLP-1s have become famous for their ability to shed weight in a manner that was previously unattainable without surgery, they were initially deployed to treat diabetes. The booming popularity of the drugs, combined with the inability of Novo and Lilly to keep up with demand, has sparked concerns over the ability of people with diabetes to access the medicine keeping their blood sugar levels in check. Off-label use of the diabetes GLP-1 formulations, Ozempic and Mounjaro, for weight loss is reportedly common, though figures are hard to monitor. Even before the drugs were approved and sold specifically for weight loss, there were regular reports of people struggling to access the drugs and research shows the number of new patients being prescribed GLP-1s for diabetes has shrunk over time as prescriptions for weight loss soar. These concerns are likely to grow as pharma firms push into new markets without addressing shortages in existing ones like the U.S.

Tangent

Novo has already secured permission to expand Wegovy’s label to include it as a treatment for cardiovascular conditions and Lilly is actively pursuing Mounjaro and Zepbound for sleep apnea in what could become the first pharmaceutical treatment for the underlying condition. Other indications are also being explored and GLP-1s have shown promise at preventing or treating a wide array of conditions including an array of cancers, Parkinson’s and dementia, liver disease, kidney disease and addiction.

What Doses Of Ozempic, Wegovy, Mounjaro And Zepbound Are Available?

All doses of Mounjaro are listed as available on the FDA shortages list, including:

  • 2.5 milligram injection
  • 5 milligram injection
  • 7.5 milligram injection
  • 10 milligram injection
  • 15 milligram injection

All doses of Zepbound are listed as available:

  • 2.5 milligram injection
  • 5 milligram injection
  • 7.5 milligram injection
  • 10 milligram injection
  • 12.5 milligram injection
  • 15 milligram injection

All doses of Ozempic are listed as available:

  • 0.68 milligram injection
  • 1.34 milligram injection
  • 2.68 milligram injection

Four out of five Wegovy doses are listed as available:

  • 0.5 milligram injection
  • 1 milligram injection
  • 1.7 milligram injection
  • 2.4 milligram injection

One Wegovy dose is listed as “limited availability”

  • 0.25 milligram injection

Further Reading

ForbesDrugs Like Ozempic, Wegovy, Zepbound And Mounjaro Could Treat Other Conditions-Here’s What Scientists Are Looking At

Get Forbes Breaking News Text Alerts: We’re launching text message alerts so you’ll always know the biggest stories shaping the day’s headlines. Text “Alerts” to (201) 335-0739 or sign up here.

Follow me on  Twitter or  LinkedInSend me a secure  tip
Total
0
Shares
Leave a Reply
Related Posts
White House chef retires after nearly 30 years, 1st woman and 1st person of color to have the job
Read More

White House chef retires after nearly 30 years, 1st woman and 1st person of color to have the job

The White House’s executive chef has retired after nearly three decades of serving meals and state dinners to five different presidents and their families White House chef retires after nearly 30 years, 1st woman and 1st person of color to have the jobBy COLLEEN LONG and DARLENE SUPERVILLEAssociated PressThe Associated PressWASHINGTON WASHINGTON (AP) — The
Senator Proposes Change to Medicare
Read More

Senator Proposes Change to Medicare

Democratic Senator Richard Blumenthal of Connecticut has introduced a bill that would make major shifts to Medicare coverage for chiropractic treatment. The Chiropractic Medicare Coverage Modernization Act (SB-799) has 14 co-sponsors as lawmakers push to increase access for non-pharmacological treatments. The bipartisan bill would expand Medicare coverage to these types of treatments instead of just
Royal Navy chef sexually assaulted male colleague after luring him into the ship’s scullery but is spared prison after military court hears he was ‘confused about his sexuality’
Read More

Royal Navy chef sexually assaulted male colleague after luring him into the ship’s scullery but is spared prison after military court hears he was ‘confused about his sexuality’

A Royal Navy chef lured his colleague into a warship's scullery before locking the door and sexually assaulting him, a court martial heard. Able Seaman Liam Pritchard told his victim, who he had already groped on another occasion, he wanted to meet, because he was suffering from a 'low mood'. The sailor, who remains anonymous
Kamala Harris Supported Eliminating Private Health Insurance
Read More

Kamala Harris Supported Eliminating Private Health Insurance

Vice President Kamala Harris went all-in for eliminating private health insurance in 2019, underscoring GovTrack’s now-deleted report of her record as the most far-left senator in that same year. GovTrack’s scorecard ranked her as the most liberal senator in 2019, further left even than socialist Sen. Bernie Sanders (I-VT). However, GovTrack rescinded that report in July, noting that